Resurrection of antibody as a therapeutic drug.
- Author:
Hong Keun CHUNG
1
;
Jun Ho CHUNG
Author Information
- Publication Type:Review ; Clinical Trial
- Keywords: antibody; drug
- MeSH: Animals; Antibodies; Antibodies, Monoclonal; Antibody Formation; Bacteriophages; Clinical Coding; Genes, Immunoglobulin; Genomics; Half-Life; Humans; Immunization; Mice; Molecular Probes; Pharmacokinetics; Proteomics; RNA, Messenger; Single-Chain Antibodies
- From:Immune Network 2001;1(1):7-13
- CountryRepublic of Korea
- Language:Korean
- Abstract: Currently 18 monoclonal antibodies were approved by FDA for inj ection into humans for therapeutic or diagnostic purpose. And 146 clinical trials are under way to evaluate the efficacy of monoclonal antibodies as anti-cancer agents, which comprise 9% of clinical trials in cancer therapy field. When considering a lot of disappointment and worries existed in this field during the past 15 years, this boom could be called as resurrection. Antibodies have several merits over small molecule drug. First of all it is easier and faster in development, as proper immunization of the target proteins usually raises good antibody response. The side effect s of antibodies are more likely to be checked out in immunohistomchemical staining of whole human tissues. Antibody has better pharmacokinetics, which means a longer half-life. And it is non-toxic as it is purely a natural drug. Vast array of methods was developed to get the recombinant antibodies to be used as drug. The mice with human immunoglobulin genes were generated. Fully human antibodies can be developed in fast and easy way from these mice through immunization. These mice could make even human monoclonal antibodies against any human antigen like albumin. The concept of combinatorial library was also actively adopted for this purpose. Specific antibodies can be screened out from phage, mRNA, ribosomal library displaying recombinant antibodies like single chain Fvs or Fabs. Then the coding genes of these specific antibodies are obtained from the selected protein-gene units, and used for industrial scale production. Both naive and immunized libraries are proved to be effective for this purpose. In post-map arena, antibodies are receiving another spotlight as molecular probes against numerous targets screened out from functional genomics or proteomics. Actually many of these antibodies used for this purpose are already human ones. Through alliance of these two actively growing research areas, antibody would play a central role in target discovery and drug development.
